Chronic kidney disease and atrial fibrillation as components of the cardiorenal continuum


Cite item

Full Text

Abstract

The paper discusses the present-day idea on a relationship between atrial fibrillation and chronic kidney disease, the specific features of therapeutic policy, and the place of antithrombotic therapy in particular. Based on the results of population-based studies, the authors set forth the specific features of cardiac arrhythmias concurrent with kidney injury, as well as promising directions to optimize management schemes for this category of patients.

References

  1. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987;31:973-980. doi: 10.1038/ki.1987.94.
  2. Iguchi Y, Kimura K, Kobayashi K et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol. 2008;102(8):1056-1059. doi:10.1016 /j.amjcard.2008.06.018.
  3. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625-635. doi: 10.1056/NEJMoa1105594.
  4. Deo R, Katz R, Kestenbaum B, Fried L, Sarnak MJ, Psaty BM, Siscovick DS, Shlipak MG. Impaired kidney function and atrial fibrillation in elderly subjects. J Card Fail. 2010;16:55-60.
  5. Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158(4):629-636.
  6. Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, Shimizu A, Hayano M, Yano K. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. Int J Cardiol. 2008;126:316-321.
  7. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946-2953. doi: 10.1161/CIRCULATIONAHA. 111.020982.
  8. McManus DD, Corteville DC, Shlipak MG, Whooley MA, Ix JH. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009;104:1551-1555. doi: 10.1016/j.amjcard.2009.07.026.
  9. Tebbe U, Bramlage P, Thoenes M et al. Prevalence of microalbuminuria and its associated cardiovascular risk: German and Swiss results of the recent global i-SEARCH survey. Swiss Med. 2009;139(33-34):473-480.
  10. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray C. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360. doi: 10.1016/S0140-6736(02)11403-6.
  11. Vaziri SM. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension. 1995;25:1155-1160. doi: 10.1161/01.HYP.25.6.1155.
  12. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, D’Agostino RB, Kannel WB, Levy D, Emelia J. Benjamin Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297:709-715. doi: 10.1001/jama.297.7.709.
  13. Wachtell K. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719. doi: 10.1016/j.accreview.2005.05.064.
  14. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461. doi: 10.1161/01.CIR.96.7.2455.
  15. Шутов А.М., Серов В.А., Курзина Е.В., Гердт А.М., Серова Д.В. Хроническая болезнь почек и фибрилляция предсердий у больных с хронической сердечной недостаточностью. Терапевтический архив. 2009;12:23-26.
  16. Lesaffre F, Wynckel A, Nazeyrollas P, Rieu P, Metz D. Echocardiography to predict adverse cardiac and vascular events in patients with severe chronic kidney disease(stage 4): a prospective study. Arch Cardiovasc Dis. 2013;106(4):220-227. doi: 10.1016/j.acvd.2013.01.005.
  17. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE, Lerma EV. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:173-181. doi: 10.2215/CJN.03170509.
  18. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-2368. doi: 10.1016/j.jacc.2007.09.021.
  19. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res. 2001;51:442-449. doi: 10.1016/S0008-6363(01)00195-X.
  20. Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J. 2006;27:2353-2361. doi: 10.1093/eurheartj/ehl233 2353-2361.
  21. Wozakowska-Kapłon B, Opolski G, Herman Z et al. Natriuretic peptides in patients with atrial fibrillation. J Cardiol. 2008;15(6):525-529. doi: 10.1111/j.1540-8159.2009.02360.x.
  22. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120;1768-1774. doi:10.1161/ CIRCULATIONAHA.109.873265.
  23. Asselbergs FW, van den Berg MP, Bakker SJ et al. N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. Neth Heart J. 2008;16(6):73-78. doi: 10.1007/bf03086122.
  24. Sakuma M, Nakamura M, Tanaka F et al. Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population. Circ J. 2010 Feb. doi: 10.1007/bf03086122.
  25. Мухин Н.А., Фомин В.В., Моисеев С.В., Швецов М.Ю., Кутырина И.М., Зайцев А.Ю., Таронишвили О.И. Кардиоренальный синдром при ишемической болезни почек (атеросклеротической реноваскулярной гипертонии). Терапевтический архив. 2008;8:30-38.
  26. Мухин Н.А., Фомин В.В. Гиперурикемия, артериальная гипертензия и хроническая болезнь почек: интерпретация взаимосвязи и стратегия действий. Клиническая нефрология. 2010;4:4-11.
  27. Mitsuhashi H, Yatsuya H, Matsushita K et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73(4):667-672. doi: 10.1253/circj.CJ-08-0626.
  28. Yoshitomi R, Fukui A, Nakayama M et al. Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease. Hypertens Res. 2014;37(3):246-252. doi: 10.1038/hr.2013.134.
  29. Navaneethan SD, Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1260-1266. doi: 10.1093/ndt/gfn621.
  30. Суворов А.В., Зубеева Г.Н., Суслова О.А., Кузьменко Ю.Н., Конюхова И.В., Вилков А.В. Нарушение сердечного ритма у больных с терминальной хронической почечной недостаточностью как предиктор сердечно-сосудистого риска. Медицинский альманах. 2011;3(16):162-164.
  31. Wetmore JB, Mahnken JD, Rigler SK et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 2012;81(5):469-476. doi: 10.1038/ki.2011.416.
  32. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119:1363-1369. doi: 10.1161/CIRCULATIONAHA.108. 816082.
  33. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-2830. doi: 10.1093/eurheartj/ehs274 2821-2830.
  34. Group. SRiAFW. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546-554. doi: 10.1212/01.wnl.0000267275.68538.8d.
  35. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295-304. doi: 10.1160/TH07-08-0508.
  36. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584.
  37. Hijazi Z, Hohnloser SH, Oldgren J et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961-970. doi: 10.1161/CIRCULATIONAHA.113.003628.
  38. Shibazaki K, Kimura K, Fujii S, Sakai K, Iguchi Y. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol. 2012;109:1303-1307. doi: 10.1016/j.amjcard.2011.12.022.
  39. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006;27:1648-1650. doi: 10.1093/eurheartj/ehl109 1648-1650.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies